ECTRIMS 2024

Diagnosis, Biomarkers, and Phenotypes

Revised McDonald criteria allow earlier and more precise MS diagnosis

Presented By

Prof. Xavier Montalban, Vall d'Hebron University Hospital, Spain

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:52

Approaches to RIS and MS converge

Presented By

Prof. Christine Lebrun-Frénay, Centre Hospitalier Universitaire de Nice, France

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:50

AI versus clinicians: who diagnoses MS faster and better?

Presented By

Ms Mahi Patel, UT Southwestern, TX, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:47

Blood markers predict MS progression

Presented By

Dr Ahmed Abdelhak, University of California San Francisco, CA, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:46

Gut microbiota modulate inflammation and cortical damage

Presented By

Dr Federico Montini, Brigham and Women's Hospital, MA, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:43

Risk factors and importance of persistent PIRA

Presented By

Dr Chao Zhu, Monash University, Australia

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:39

Vitamin D supplementation in progressive MS should be medically supervised

Presented By

Dr Michaela Haindl, Medical University of Graz, Austria

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:38

Treatment: Strategies

Treatment: Trials

Tolebrutinib slows disability worsening in relapsing MS

Presented By

Dr Jiwon Oh, St. Michael's Hospital, Canada

Trial

Phase 3, GEMINI 1, GEMINI 2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:21

Frexalimab shows favourable safety and efficacy in OLE

Presented By

Prof. Gavin Giovannoni, Queen Mary University of London, UK

Trial

Phase 2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:17

Good safety of ozanimod over up to 8 years of treatment

Presented By

Prof. Krzysztof Selmaj, University of Warmia and Mazury, Poland

Trial

DAYBREAK

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:16

Tolebrutinib slows disability in non-relapsing SPMS

Presented By

Prof. Robert Fox, Cleveland Clinic, OH, USA

Trial

Phase 3, HERCULES

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:13

High-dose simvastatin does not slow disability progression in SPMS

Presented By

Dr Jeremy Chataway, University College London, UK

Trial

Phase 3, MS-STAT2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:11

Pregnancy and Comorbidity Risks

Transfer of ocrelizumab into breastmilk is negligible

Presented By

Dr Riley Bove, University of California San Francisco, CA, USA

Trial

Phase 4, SOPRANINO

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:08

High genetic burden for depression associated with MS disease activity

Presented By

Dr Kaarina Kowalec, University of Manitoba, Canada

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:06

More comorbidity is associated with worse clinical outcomes in MS

Presented By

Dr Amber Salter, UT Southwestern, TX, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:05

NMOSD/MOGAD